Resverlogix Corp.

Industry Leaders Select Resverlogix's RVX-208 Among Top 10 Most Promising Drugs

    Calgary, Canada (ots/PRNewswire) - Resverlogix Corp's ("Resverlogix" or the "Company") (TSX:RVX) novel lead  ApoA-I drug candidate, RVX-208 has been selected as one of the top 10 most promising cardiovascular disease (CVD) drugs available for strategic partnering by an independent committee assembled by Windhover Information, a  leading provider of business information products and services to senior  executives in the pharmaceutical, biotechnology, and medical device  industries.

    "We are honored to be part of this select group of top ten most promising  innovative drugs," stated Donald McCaffrey, President and CEO of Resverlogix.  "It again validates RVX-208 and our entire NexVas(TM) PR franchise as an  important new small molecule drug for the largest market with unmet needs,  atherosclerosis and cardiovascular diseases. We are moving towards our next  important milestone, Phase 1b/2a, later this fall and continue to measure safety, tolerability and key reverse cholesterol transport (RCT) markers such  as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."

    The selection committee was led by Marc Wortman, PhD, contributing writer  to Windhover's IN VIVO and Start Up publications, and Michael Rice, Senior  Consultant, and Ed Saltzman, President of Defined Health, a leading business  development strategy consulting firm. Drawing on the analytic resources of  these organizations, the group evaluated hundreds of compounds currently in development for the treatment of cardiovascular disease prior to selecting  RVX-208 among the top ten most attractive drug available for partnering.

    "Selected companies have been screened using a strict set of judging  criteria for the Top 10 award, and represent what our committee considered  the most attractive cardiovascular opportunities the industry has to offer,"  stated Roger Longman, Managing Director of Windhover Information. "Winners  have met strict criteria including: unmet medical need, market potential,  diversity of indications, strong science, multi-level partnering  opportunities (biotech and pharma), potential for new opportunities beyond  initial indications, history of the molecule and drug and be a strong company."

    "To have a highly regarded selection committee realize the commercial  potential for RVX-208 is important for us," stated Kenneth Lebioda, Senior  Vice President of Business and Corporate Development at Resverlogix.  "Atherosclerosis, the leading underlying cause of cardiovascular death,  represents the largest cost center to health systems globally. Novel small  molecules that enhance ApoA-I production have a diverse number of patient  groups that they can help such as low HDL, acute coronary syndrome, diabetes,  post myocardial infarction and Alzheimer's. A novel drug that could help these diseases will have a major positive impact on patients and health  systems alike. This is where RVX-208 offers an unrivalled commercial  opportunity for the life science industry," added Mr. Lebioda.

    As a selected company, Resverlogix has been invited to present data on  RVX-208 at Windhover's Therapeutic Area Partnerships conference on November  3-5, 2008 in Philadelphia.

    About Windhover

    Windhover Information Inc., an Elsevier company, has led the field in  providing analysis of the healthcare industry to decision-makers at all  levels since the founding of its flagship publication, IN VIVO, The Business  & Medicine Report, in 1983. Windhover provides its information and analysis  in many formats, including print, electronic databases, international  conferences and webinars. For more on the company's products and services,  please see

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the  development of novel therapies for important global medical markets with  significant unmet needs. The NexVas(TM) program is the Company's primary  focus which is to develop novel small molecules that enhance ApoA-I. These  vital therapies address the grievous burden of atherosclerosis and other  important diseases such as acute coronary syndrome, diabetes, Alzheimer's  and other vascular disorders. The Company's secondary focus is TGF-Beta  Shield(TM), a program that aims to address burgeoning grievous diseases,  such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

    This news release may contain certain forward-looking statements that  reflect the current views and/or expectations of Resverlogix Corp. with  respect to its performance, business and future events. Such statements are  subject to a number of risks, uncertainties and assumptions. Actual results  and events may vary significantly. The TSX Exchange does not accept  responsibility for the adequacy or accuracy of this news release.

    For further information: Theresa Kennedy, VP, Corporate Communications,  Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email:; Sarah Zapotichny, Manager, Investor Relations,  Resverlogix Corp., Phone: +1-403-254-9252, Fax: +1-403-256-8495, Email:, Website: (RVX.)

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar:

For further information: Theresa Kennedy, VP, Corporate
Communications,  Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email:; Sarah Zapotichny,
Manager, Investor Relations,  Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email:

Weitere Meldungen: Resverlogix Corp.

Das könnte Sie auch interessieren: